Medicine and Dentistry
Hearing Impairment
100%
Ototoxicity
75%
Cisplatin
69%
Childhood Cancer
48%
Sodium Thiosulfate
43%
Malignant Neoplasm
41%
Pediatrics
36%
Oncology
35%
Cancer Therapy
24%
Adolescent
23%
Prevalence
23%
Blood Brain Barrier
22%
Germinoma
22%
Carboplatin
18%
Adverse Event
17%
Late Effect
16%
Tinnitus
16%
Systematic Review
14%
Cancer in Young Adults
13%
Hearing Assessment
13%
Audiometry
11%
Ganglioneuroblastoma
11%
Pediatric Cancer
11%
Drug Megadose
11%
Distortion Product Otoacoustic Emission
11%
Cancer Stem Cell
11%
Hematopoietic Stem Cell Transplantation
11%
Cohort Analysis
11%
Phase I Trials
11%
Brain Tumor
11%
Acetylcysteine
11%
Central Nervous System
11%
Supportive Care
11%
Intraarterial Drug Administration
11%
DNA Template
11%
Quality of Life
9%
Speech Production
6%
Neoplasm
6%
Metastatic Carcinoma
6%
Arm
5%
Patient-Reported Outcome
5%
Infusion
5%
Patient Referral
5%
Keyphrases
Ototoxicity
38%
Hearing Impairment
35%
Cisplatin-induced Hearing Loss
33%
Children's Oncology Group
33%
Hearing Loss in children
24%
Young Cancer Patients
22%
Sodium Thiosulfate
22%
Carboplatin
16%
Cisplatin
15%
Childhood Cancer
14%
N-acetylcysteine
14%
Common Terminology Criteria for Adverse Events (CTCAE)
14%
Tinnitus
13%
Extended High-frequency Audiometry
11%
Cisplatin-based Chemotherapy
11%
Childhood Cancer Treatment
11%
Childhood Cancer Survivors
11%
Phase I Trial
11%
Cerebrospinal Fluid Shunting
11%
Children with Cancer
11%
Cancer Guidelines
11%
Young Adult Cancer Survivors
11%
Grading Scale
11%
High-risk Neuroblastoma
11%
Toxicity Profile
11%
Prevalence Risk
11%
Late Effects
11%
Academic Development
11%
Blood-brain Barrier Disruption
11%
Brain Tumor Survivors
11%
Difference Curve
11%
High Dose
11%
Hierarchical Gaussian Process
11%
Remote Fields
11%
Cancer Stem Cells
11%
Pediatric Cancer
11%
Hematopoietic Stem Cell Transplantation
11%
Patient-reported Measures
11%
Adult Cancer
8%
Systemic Medications
7%
Disulfiram
7%
Amifostine
7%
Severe Hearing Loss
7%
Intratympanic Therapy
7%
Sodium Diethyldithiocarbamate
7%
Oncology Survivorship
7%
Speech-language
7%
Academic Communication
6%
Audiologists
6%
Platinum-based Chemotherapy
5%
Nursing and Health Professions
Hearing Impairment
66%
Ototoxicity
66%
Malignant Neoplasm
42%
Cisplatin
40%
Distortion Product Otoacoustic Emission
22%
Cancer Therapy
17%
Logopedics
16%
Sodium Thiosulfate
16%
Childhood Cancer
16%
Audiometry
16%
Quality of Life
14%
Adverse Event
14%
Tinnitus
12%
Germ Cell Tumor
11%
Cerebrospinal Fluid Shunting
11%
Blood-Brain Barrier
11%
Intraarterial Drug Administration
11%
Hematopoietic Stem Cell Transplantation
11%
Systematic Review
11%
Adolescent
10%
Nomenclature
8%
Toddlers
7%
Pediatrics Patient
7%
Audiologist
7%
Patient-Reported Outcome
5%
